Skip to main content

Advertisement

SpringerLink
Log in

Bone Targeted Therapies in Early Breast Cancer

  • Breast Cancer (Carla I. Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Bisphosphonates have emerged as an important tool in the supportive care of women with early breast cancer. Whereas traditionally, these drugs have been part of the treatment of osseous metastasis, the key role of bisphosphonates in preserving bone health in patients with early breast cancer cannot be overemphasised. Currently the most established use of bisphosphonates in early breast cancer patients is in women receiving hormonal blockade, mostly aromatase inhibitors (AI), with concomitant osteopenia. To that end, it is recommended that every woman undergo a Dual Energy X-Ray absorptiometry (DEXA) scan before commencement of an AI and annually during the treatment duration. In addition, unless contraindicated, all women should receive calcium and Vitamin D supplementation. The use of bisphosphonates as part of the adjuvant therapy strategy, regardless of baseline bone density condition, has produced thought-provoking results, although this is not yet considered standard clinical practise.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? an evidence- based review. J Clin Oncol. 1998;16:1218–25.

    PubMed  CAS  Google Scholar 

  2. Saad F, Gleason DM, Murray R, et al. A randomised placebo- controlled trial of zoledronic acid in patients with metastatic prostate carcinoma. J Natl Canc Inst. 2002;94:1458–68.

    Article  CAS  Google Scholar 

  3. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–7.

    Article  PubMed  CAS  Google Scholar 

  4. Van Poznak C, Sauter NP, et al. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005;104(3):443.

    Article  PubMed  Google Scholar 

  5. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.

    Article  PubMed  CAS  Google Scholar 

  6. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone –related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Investig. 1996;98:1544–9.

    Article  PubMed  CAS  Google Scholar 

  7. Rodan GA, Fleisch HA, et al. Bisphosphonates: mechanisms of action. J Clin Investig. 1996;97(12):2692.

    Article  PubMed  CAS  Google Scholar 

  8. Stresing V, Daubine F, Benzaid I, et al. Bisphosphonates in cancer therapy. Cancer Lett. 2007;8;257(1):16–35

    Google Scholar 

  9. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer. 2003;98:1802–10.

    Article  PubMed  CAS  Google Scholar 

  10. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.

    Article  PubMed  CAS  Google Scholar 

  11. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.

    Article  PubMed  CAS  Google Scholar 

  12. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–62.

    Article  PubMed  CAS  Google Scholar 

  13. The Breast International Group (BIG) 1–98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.

    Article  Google Scholar 

  14. Vorobiof DA, Kleeberg VR, Perez Carrion R, et al. A randomized open parallel group trial to compare the endocrine effects of oral anastrozole (arimidex) with intramuscular formestane in post menopausal women with advanced breast cancer. Ann Oncol. 1999;10:1219–55.

    Article  PubMed  CAS  Google Scholar 

  15. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrazole on bone mineral density: 5 year results from the anastrazole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26:1051–7.

    Article  PubMed  CAS  Google Scholar 

  16. Coleman RE, Banks LM, Girgis SL, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–27.

    Article  PubMed  CAS  Google Scholar 

  17. Brufsky A, Harker G, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5 year final follow-up. Cancer Res. 2009;69:(24 Suppl); Abstract 4083. Upfront zoledronic acid delays the onset of osteoporosis in postmenopausal women treated with aromatase inhibitors, as well as a reduction in disease free survival events.

  18. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with breast cancer receiving adjuvant letrozole: 36- month results of the ZO-FAST study. Ann Oncol. 2010:21(11):2188–2194.

    Article  PubMed  CAS  Google Scholar 

  19. Eastell R, Adams J, Clack G, et al. Long term effects of anastrozole on bone mineral density: 7 year results from the ATAC trial. Ann Oncol. 2011;22:857–862.

    Article  PubMed  CAS  Google Scholar 

  20. Van Poznak C, Hannon RA, Clark G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate. The SABRE trial. J Clin Oncol. 2010;28:967–75.

    Article  PubMed  Google Scholar 

  21. Lester J, Dodwell D, Purohit OP, et al. Prevention of anastrazole induced bone loss with monthly ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Canc Res. 2008;14:6336–42.

    Article  CAS  Google Scholar 

  22. Gnant M, Milneritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–691.

    Article  PubMed  CAS  Google Scholar 

  23. Gnant M, Milneritsch B, Luschin-Ebengreuth G, et al. Austrian Breast and Colorectal Cancer Study Group adjuvant endocrine therapy plus zoledronic acid in premenopausal woman with early stage breast cancer. 5 year follow up of the ABCSG-12 bone mineral substudy. Lancet Oncol. 2008;9:840–9.

    Article  PubMed  CAS  Google Scholar 

  24. Paget S et al. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–3.

    Article  Google Scholar 

  25. Bussard KM, Gay CV, Mastro AM, et al. The bone microenvironment in metastasis; what is special about bone? Canc Metastasis Rev. 2008;27:41–55.

    Article  Google Scholar 

  26. Psaila B, Lyden D, et al. The metastatic niche: adapting the foreign soil. Nat Rev Canc. 2009;9:285–93.

    Article  CAS  Google Scholar 

  27. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–63.

    Article  PubMed  CAS  Google Scholar 

  28. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. J Clin Oncol. 2002;20;32:19–3224

    Google Scholar 

  29. Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow up of a randomised controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43:650–6.

    Article  PubMed  CAS  Google Scholar 

  30. Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30:1807–13.

    PubMed  CAS  Google Scholar 

  31. Greenberg S, Park J, Melisko M, et al. Effect of adjuvant zoledronic acid on disseminated tumor cells in the bone marrow of women with early-stage breast cancer: updated results. J Clin Oncol. 2010;28 suppl 114s:Abstract 1002

  32. Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer, an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–8.

    Article  PubMed  CAS  Google Scholar 

  33. Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG01/04) SABCS. 2010 abstract S4–5. This study tested zoledronic acid in the postmenopausal women with stage II–III breast cancer, in addition to hormonal blockade following adjuvant chemotherapy, and did not show benefit to the addition of zoledronic acid. However, a subset analysis suggests that women who had been menopausal for more than 5 years seemed to derive more benefit from the addition of zoledronic acid. This is an interesting observation, and needs to be further evaluated in clinical trials.

  34. Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br J Cancer. 2010;102(7):1099–1105.

    Article  CAS  Google Scholar 

  35. Chlebowski R, Chen Z, Cauley J, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010;28:3582–90.

    Article  PubMed  CAS  Google Scholar 

  36. Rennert G, Pinchev M, Rennert HS, et al. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28:3577–3581.

    Article  PubMed  CAS  Google Scholar 

  37. Coleman R, Bundred N, De Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole. Canc Res. 2009;69(24):suppl 3–suppl 4082.

    Article  Google Scholar 

  38. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor associated bone loss in postmenopausal women: practical guidance for prevention and treatment. Ann Oncol. 2011 April 2(epub ahead of print). This manuscript provides practical advice for clinicians in the management of bone health in breast cancer patients receiving adjuvant hormonal blockade.

  39. Aebi S, Davidson S, Gruber G, on behalf of the ESMO guidelines working group, et al. Ann Oncol. 2010;21(5):v9–v14.

    Article  PubMed  Google Scholar 

  40. Personal communication, St Gallen breast cancer conference, 2011

  41. Hillner B, Ingle J, Chlebowski R, et al. American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–57.

    Article  PubMed  CAS  Google Scholar 

  42. Stopeck AT, Lipton A, Body J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer. A randomised double blind study. J Clin Oncol. 2010;28:5132–9.

    Article  PubMed  CAS  Google Scholar 

  43. Ellis GK, Bone H, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for non metastatic breast cancer. J Clin Oncol. 2008;4875–4882

Download references

Disclosure

D. Vorobiof: Consultancy for Amgen, MSD, and Roche, received honoraria, payments for development of educational presentations and had travel/accommodations expenses covered/reimbursed from Amgen, MSD, and Roche; K. Tabane: Received honoraria from Roche and had travel/accommodations expenses covered/reimbursed from Roche and AstraZeneca.

Author information

Authors and Affiliations

  1. Sandton Oncology Centre, 159 Rivonia Road, Sandton, , P O Box 2059, Parklands, 2121, Johannesburg, South Africa

    Keo Tabane MD & Daniel A. Vorobiof MD

Authors
  1. Keo Tabane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Vorobiof MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel A. Vorobiof MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tabane, K., Vorobiof, D.A. Bone Targeted Therapies in Early Breast Cancer. Curr. Treat. Options in Oncol. 12, 412–423 (2011). https://doi.org/10.1007/s11864-011-0163-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0163-3

Keywords

Search

Navigation